A Randomized, Multi-Center, Parallel-Group, Safety and Efficacy Study of Lotemax Gel 0.5% and Restasis 0.05% for 12 Weeks in Subjects With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease; DED)

Trial Profile

A Randomized, Multi-Center, Parallel-Group, Safety and Efficacy Study of Lotemax Gel 0.5% and Restasis 0.05% for 12 Weeks in Subjects With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease; DED)

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2014

At a glance

  • Drugs Loteprednol etabonate (Primary) ; Ciclosporin
  • Indications Keratoconjunctivitis sicca
  • Focus Therapeutic Use
  • Sponsors Bausch & Lomb
  • Most Recent Events

    • 20 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top